First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yelena Y. Janjigian, Hirokazu Shoji, Anna Kowalczyk, Sun Young Rha, Filippo Pietrantonio, Kohei Shitara, Aitana Calvo Ferrándiz, Hanneke W.M. Van Laarhoven, Tianshu Liu, Boguslawa Karaszewska, Keun-Wook Lee, Kathia Cristina Abdalla, Eric Xueyu Chen, Jamil Asselah, M. Luisa Limon, Megan Scott, Caron Lloyd, Eric Nwazue, Roy Rabbie, Jeeyun Lee
Institutions: Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital, University Clinical Centre, Gdańsk Medical University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, National Cancer Center Hospital East, Hospital General Universitario Gregorio Marañón, Amsterdam University Medical Centers, University of Amsterdam, Fudan University, Zhongshan Hospital, Seoul National University, Seoul National University Bundang Hospital, Hospital de Base, University Health Network, Princess Margaret Cancer Centre, McGill University Health Centre, Hospital Universitario Virgen del Rocío, AstraZeneca (United Kingdom), AstraZeneca (United States), Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162534320